Chopped drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold as well as preparation method and application thereof

By modifying protein drugs and electrospinning shearing, short-cut drug-loaded nanofiber aerogels were prepared and combined with porous bioactive ceramics. This solved the problem of drug distribution within the ceramics, enabling sustained drug release and promoting osteoblast growth, thus improving bone repair.

CN118976154APending Publication Date: 2024-11-19SHANGHAI JIAOTONG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069753.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing technologies make it difficult to effectively distribute nanofibers loaded with protein drugs within porous bioactive ceramics, resulting in difficulty in drug release and affecting osteogenic effects.

Method used

Drug-loaded nanofiber membranes were prepared by solubilizing protein drugs with polyethylene glycol. Short-cut drug-loaded nanofibers were then formed by electrospinning and mechanical shearing, and subsequently composited with porous bioactive ceramics. The nanofiber aerogels were then bonded to the ceramics using a vacuum stirring impregnation method.

Benefits of technology

This technology enables the uniform distribution and continuous release of growth factors or protein drugs within porous bioactive ceramics, promoting osteoblast growth within the ceramics and enhancing bone repair efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976154A_ABST
    Figure CN118976154A_ABST
Patent Text Reader

Abstract

The invention relates to a chopped drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out polyethylene glycol solubilization modification on a protein drug to obtain polyethylene glycol modified protein drug freeze-dried powder; the preparation method comprises the following steps: uniformly dispersing polyethylene glycol modified protein drug freeze-dried powder in a polymer electrostatic spinning solution, and carrying out electrostatic spinning to obtain a drug-loaded polymer nanofiber membrane; preparing the drug-loaded polymer nanofiber membrane into a chopped drug-loaded polymer nanofiber; the preparation method comprises the following steps: preparing a dispersion liquid from short-cut drug-loaded polymer nanofibers, immersing porous bioactive ceramic into the dispersion liquid containing the short-cut drug-loaded polymer nanofibers, and carrying out vacuum stirring impregnation and freeze-drying to obtain the short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold. According to the scheme, growth factors or protein drugs can be released in the porous bioactive ceramic.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomaterials, and in particular to a short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold, and a preparation method and application thereof. Background Art

[0002] In tissue engineering, bionic repair systems generally simulate processes such as biological cell adhesion, reproduction, differentiation, and connective tissue generation. Porous bioactive ceramics, such as β-tricalcium phosphate (Ca3(PO4)2, Tricalcium phosphate, TCP), hydroxyapatite Ca 10 (PO4)6(OH)2, calcium phosphate, etc., can cause cell adhesion and bone conduction at the interface, but the osteogenic differentiation ability inside porous materials is often limited by space and material transport. Some existing studies usually load growth factors, such as BMPs, TGF-β, IGF, SDF, etc., on nanoparticles or fiber materials and composite them with porous ceramics to further promote cell adhesion, reproduction and bone differentiation. However, the existing composite methods have certain limitations. Drug-loaded fibers are easily coated on the surface of porous bioceramics, which enhances the osteogenic differentiation of the surface [Sheng Luyao. Preparation and performance characterization of porous HA scaffolds coated with BMP short fibers. Southwest Jiaotong University, Master's thesis, 2015]. However, due to its length (several hundred microns), it is difficult for the fibers to enter the porous bioceramics by impregnation or filtration to promote the growth of osteoblasts inside the porous bioceramics, especially in the core area. The biological activity of the surface of porous bioactive ceramics can be significantly enhanced, but the internal osteogenic effect is not ideal. Drug-loaded particles can enter the interior of porous materials through methods such as vacuum impregnation and remain on the surface through physical or chemical adsorption. However, drug-loaded particles only adhere to the surface of porous materials, changing the surface roughness. Drugs can be released near the internal pore surface, but it is difficult to promote cell proliferation in the entire internal pore space.

[0003] Microspheres or aerogels composed of fibers have a similar structure to the extracellular matrix, which is conducive to cell adhesion and proliferation, enhances cell-to-cell interactions, and promotes tissue differentiation and regeneration [Zhang Z, Eyster TW, Ma PX. Nanostructured injectable cell microcarriers for tissue regeneration. Nanomedicine. 2016; 11(12): 1611–28. Daraeinejad Z, Shabani I. Enhancing Cellular Infiltration on Fluffy Polyaniline-Based Electrospun Nanofibers. Front Bioeng Biotechnol. 2021; 9(June): 641371.]. However, since bioactive ceramics generally require high-temperature sintering (such as 900°C to 1200°C, 1-3h), protein drugs such as growth factors can only be loaded after porous ceramics are sintered. Considering the mechanical strength (cancellous bone strength 1-10MPa, compact bone strength 1-100MPa), the pore size of porous bioactive ceramics is generally in the range of 100-300μm, and the porosity is 40-90% [Darus F, IsaRM, Mamat N, Jaafar M. Techniques for fabrication and construction of three-dimensional bioceramic scaffolds: Effect on pores size, porosity and compressive strength. Ceram Int [Internet]. 2018; 44(15): 18400–7. Sabree I, GoughJE, Derby B. Mechanical properties of porous ceramic scaffolds: Influence of internal dimensions. Ceram Int. 2015; 41(7): 8425–32.]. Studies have shown that interconnected pores with a pore size greater than 300μm are most conducive to bone tissue formation. When micron-sized short fibers, microspheres, etc. are vacuum impregnated or gel-compounded, the second phase will be deposited on the surface of the internal pores or around the connecting pores, which will reduce the size of the connecting pores or even block the pores.

[0004] Chinese patent CN114191615A discloses a multilayer composite material and preparation method for promoting the repair of articular cartilage-calcification layer-subchondral bone damage. The material is composed of a porous polymer-based composite unit, a gradient fiber membrane unit and a porous ceramic unit from top to bottom. The porous polymer-based composite unit is composed of a composite composed of a fibrin gel loaded with growth factors infused into a polymer pore network, the gradient fiber membrane unit is composed of a double-layer ultrafine fiber microporous membrane, and the porous ceramic unit is composed of bioactive inorganic ceramics; wherein the stem cells in the porous polymer unit can be induced to differentiate into chondrocytes by the growth factors carried, the upper layer of the gradient fiber membrane unit contains functional molecules that promote cartilage regeneration, and the lower layer contains bioactive inorganic particles, and the pore size of the porous ceramic unit is 200-800μm. This patent scheme is a layered structure, and does not involve the structure of short-cut polymer nanofiber aerogel filled into the pores of porous bioactive ceramics. Summary of the invention

[0005] The purpose of the present invention is to provide a short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold and its preparation method and application. The solution of the present invention can overcome the difficulty that the polymer nanofiber membrane loaded with protein drugs is difficult to retain inside the porous bioactive ceramic.

[0006] The purpose of the present invention can be achieved by the following technical solutions:

[0007] The present invention provides a method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic, comprising the following steps:

[0008] (1) performing polyethylene glycol solubilization modification on the protein drug to obtain a polyethylene glycol-modified protein drug lyophilized powder;

[0009] (2) preparing a polymer electrospinning solution, adding a lyophilized powder of a protein drug modified with polyethylene glycol to the polymer electrospinning solution, and then performing electrospinning to obtain a drug-loaded polymer nanofiber membrane;

[0010] (3) preparing the drug-loaded polymer nanofiber membrane into short-cut drug-loaded polymer nanofibers through chemical and mechanical shearing;

[0011] (4) The short-cut drug-loaded polymer nanofibers are prepared into a dispersion, and the porous bioactive ceramic is immersed in the dispersion containing the short-cut drug-loaded polymer nanofibers. The short-cut drug-loaded polymer nanofibers and the porous bioactive ceramic are composited by vacuum stirring impregnation and freeze-drying to obtain a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic.

[0012] In one embodiment of the present invention, in step (1), the protein drug is selected from a single protein (eg, bovine serum albumin) or a complex protein (eg, a combination of bovine serum albumin and one or more growth factor proteins such as SDF-1α).

[0013] In some embodiments of the present invention, bovine serum albumin is used as an example for illustration. In addition, other protein drugs may also be selected.

[0014] In one embodiment of the present invention, in step (1), the method for obtaining a polyethylene glycol-modified protein drug lyophilized powder comprises the following steps:

[0015] (1.1) preparing a buffer solution, dissolving the protein drug in the buffer solution, and adding the growth factor to the buffer solution to obtain a protein solution;

[0016] (1.2) dissolving polyethylene glycol in a buffer solution and stirring until the solution is uniformly dissolved to obtain a polyethylene glycol solution;

[0017] (1.3) The protein solution and the polyethylene glycol solution are mixed and stirred, and then frozen to obtain a polyethylene glycol-modified protein drug freeze-dried powder.

[0018] In one embodiment of the present invention, in step (1.1), in the protein solution, the concentration of the protein drug is 1-20 mg / ml, preferably 1-10 mg / ml, and the concentration of the growth factor is 0.5-1 mg / ml.

[0019] In one embodiment of the present invention, the growth factor is selected from one or a combination of BMPs, TGF-β, IGF or SDF.

[0020] In one embodiment of the present invention, in step (1.2), the polyethylene glycol solution is prepared according to a weight ratio of polyethylene glycol to protein drug of 2-10:1 (preferably 5:1).

[0021] In one embodiment of the present invention, in step (1.3), the freezing conditions are: -40 to -60°C, and freeze-drying for 6-12 hours.

[0022] In one embodiment of the present invention, in step (1.1) and step (1.2), the buffer solution is a PBS buffer solution.

[0023] In a more specific embodiment of the present invention, in step (1), the method for obtaining a polyethylene glycol-modified protein drug lyophilized powder comprises the following steps:

[0024] First, prepare 0.5w / v% BSA (66kDa) 1X PBS buffer solution, weigh 0.2g BSA powder and dissolve it in 40ml 1X PBS buffer solution, stir at room temperature for 10-15min until it is evenly dissolved, add 0.5-1mg / ml growth factor to the BSA 1X PBS buffer solution in this step to obtain a protein solution.

[0025] PEG (6 kDa) / BSA was prepared in a solute mass ratio of 5:1, 1 g of PEG powder was weighed and dissolved in 10 ml of 1X PBS buffer solution, and magnetic stirring was performed in a 50°C oil bath until the solution was uniformly dissolved to obtain a PEG solution.

[0026] Subsequently, the protein solution was mixed with the PEG solution (a total of 50 ml) and stirred magnetically at room temperature overnight. The mixed solution was then poured into a centrifuge tube, which was frozen with liquid nitrogen. Subsequently, the tube was sealed with aluminum foil and placed in a freeze dryer with a freezing parameter of -50°C / 3.0Pa and freeze-dried overnight to obtain PEG-modified BSA freeze-dried powder.

[0027] In one embodiment of the present invention, in step (2), the electrospinning medium in the polymer electrospinning solution is a medical polymer material, selected from one or a combination of polylactic acid (poly(lactic acid) (PLA)), polycaprolactone (poly(ε-caprolactone) (PCL)), polylactic acid-glycolic acid copolymer (poly(lactic-co-glycolic acid) (PLGA)) or polycarboxylic acid (poly(glycolic acid) (PGA)).

[0028] In one embodiment of the present invention, in step (2), the spinning solvent in the polymer electrospinning solution is a mixed solution of dichloromethane and dimethylpropionamide, wherein the volume ratio of dichloromethane to dimethylpropionamide is 7:3 to 9:1.

[0029] In one embodiment of the present invention, in step (2), the concentration of the electrospinning medium in the polymer electrospinning solution is 5-15 w / v%.

[0030] In one embodiment of the present invention, in step (2), after the polyethylene glycol-modified protein drug lyophilized powder is added to the polymer electrospinning solution, the concentration of the polyethylene glycol-modified protein drug lyophilized powder is 10-50 mg / ml.

[0031] In one embodiment of the present invention, in step (2), the conditions for electrospinning are: 20-28°C, 50-60% RH, positive pressure: 15-17 kV, negative pressure: -1--4 kV, spinning distance 13-19 cm, collected on a carrier such as release paper or aluminum foil using a roller shaft, roller speed: 200-1000 rpm.

[0032] In one embodiment of the present invention, in step (2), when performing electrospinning, the syringe specifications that can be used are: 2.5ml, 5ml or 10ml, and the spinning solution advancement speed is 1.5ml / h.

[0033] In one embodiment of the present invention, in step (2), the fiber diameter of the drug-loaded polymer nanofiber membrane is 0.1-1 μm.

[0034] In one embodiment of the present invention, in step (3), the drug-loaded polymer nanofiber membrane is sheared into short-cut drug-loaded polymer nanofibers by using an aminolysis reaction combined with a mechanical shearing action.

[0035] In one embodiment of the present invention, in step (3), the method of shearing the drug-loaded polymer nanofiber membrane into short-cut drug-loaded polymer nanofibers is:

[0036] The drug-loaded polymer nanofiber membrane is cut into block-shaped drug-loaded polymer nanofiber blocks. Subsequently, an excess of 1,6-hexanediamine is weighed and dissolved in isopropanol. The drug-loaded polymer nanofiber blocks are added to the 1,6-hexanediamine isopropanol solution, heated to 35-40°C (for example, 37°C), stirred at a speed of 500-800rpm, and kept warm for 3-5 hours to obtain short-cut drug-loaded polymer nanofibers with a nanofiber length in the range of 2-20μm. The solution is then centrifuged (the centrifugation condition can be 10000 rpm for 10min), and then washed with anhydrous ethanol or isopropanol (at least 3 times), and then the short-cut drug-loaded nanofibers are dispersed with tert-butyl alcohol, frozen with liquid nitrogen, and freeze-dried to obtain short-cut drug-loaded polymer fibers.

[0037] In one embodiment of the present invention, the role of hexamethylenediamine is to decompose the polymer, so the amount of hexamethylenediamine can be calculated based on the total amount of the drug-loaded polymer nanofiber membrane. During operation, the amount of hexamethylenediamine added is generally greater than the calculated amount.

[0038] The reaction equation for the decomposition of polymers using hexamethylenediamine is referenced from: Oustadi F, Imani R, Haghbin Nazarpak M, Sharifi AM. Genipin-crosslinked gelatin hydrogel incorporated with PLLA-nanocylinders as a bone scaffold: Synthesis, characterization, and mechanical properties evaluation. Polym Adv Technol. 2020; 31: 1783–1792.

[0039] The reaction mechanism is as follows:

[0040]

[0041] In one embodiment of the present invention, in step (4), short-cut drug-loaded polymer nanofibers are dispersed in tert-butyl alcohol to prepare a dispersion, and the porous bioactive ceramic is immersed in the dispersion containing the short-cut drug-loaded polymer nanofibers, and a vacuum revolution and rotation stirring treatment is performed to achieve the composite of the short-cut drug-loaded polymer nanofibers and the porous bioactive ceramic. The short-cut drug-loaded polymer nanofibers are taken out and then frozen in liquid nitrogen to obtain a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic.

[0042] In one embodiment of the present invention, in step (4), the concentration of short-cut drug-loaded polymer nanofibers in the dispersion is 5-50 mg / ml.

[0043] In one embodiment of the present invention, in step (4), the ratio of the apparent volume of the porous bioactive ceramic to the volume of the dispersion is 5%-50%. The apparent volume of the porous bioactive ceramic here refers to the volume of the appearance of the porous bioactive ceramic, including the volume occupied by pores.

[0044] In one embodiment of the present invention, the porous bioactive ceramic is selected from β-tricalcium phosphate (Ca3(PO4)2, Tricalcium phosphate, TCP), hydroxyapatite Ca 10 (PO4)6(OH)2, calcium phosphate, etc., or a combination of several thereof.

[0045] In one embodiment of the present invention, in step (4), the conditions for the vacuum revolution and rotation stirring treatment are: rotation speed of 1800 rpm, 3-10 min, and air pressure of 0.5 Pa.

[0046] The present invention further provides a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramics prepared based on the above preparation method.

[0047] The present invention further provides the use of the short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold prepared based on the above preparation method as a bone repair material.

[0048] The present invention realizes the composite of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic by filling short-cut polymer nanofiber aerogel loaded with growth factors or protein drugs into the pores of porous bioactive ceramics. On the one hand, the growth factors or drugs are released inside the porous bioactive ceramics. On the other hand, the short-cut polymer nanofiber aerogel three-dimensionally distributed in the pores of the porous bioactive ceramics is beneficial to bone cell adhesion and bone tissue growth.

[0049] The solution based on the present application can achieve: 1) short-cut polymer nanofiber aerogel loaded with growth factors or protein drugs is evenly distributed inside the porous bioactive ceramic, and 2) when the composite scaffold is used, the growth factors or protein drugs are released inside the porous bioactive ceramic, which helps osteoblasts grow inside the porous bioactive ceramic.

[0050] Compared with the prior art, the technology of the present invention can realize the release of bioactive protein drugs inside porous bioactive ceramics, has a sustained drug release effect, and is conducive to the growth of osteoblasts in the later stage of bone repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 Scanning electron microscopy images of the macro and cross-section of short-cut BSA / PLA nanofibers.

[0052] Figure 2 Macroscopic picture of the composite of chopped BSA / PLA nanofiber aerogel and porous bioceramic β-TCP.

[0053] Figure 3 Microscopic image of the interior of the porous bioceramic β-TCP aerogel loaded with chopped BSA / PLA nanofibers.

[0054] Figure 4 This is the cumulative release curve of BSA protein.

[0055] Figure 5 This is a scanning electron micrograph of the interior of the composite of short-cut drug-loaded polymer nanofibers and porous bioceramic β-TCP using sodium alginate gel as a carrier.

[0056] Figure 6 This is a scanning electron microscopy image of SDF-1α / polylactic acid nanofibers.

[0057] Figure 7 Micro-CT test results of rat skull defect models using different scaffolds. (a) Blank control (no scaffold), (b) porous bioceramic β-TCP, (c) short-cut polylactic acid nanofiber aerogel and porous bioceramic β-TCP composite scaffold, (d) short-cut SDF-1α / polylactic acid nanofiber aerogel and porous bioceramic β-TCP composite scaffold. DETAILED DESCRIPTION

[0058] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0059] Example 1

[0060] Preparation of a porous bioceramic β-TCP composite scaffold loaded with bovine serum albumin / polylactic acid nanofiber aerogel.

[0061] The preparation method is as follows:

[0062] 1. Polyethylene glycol (PEG) solubilization modification of bovine serum albumin (BSA)

[0063] First, prepare 0.5w / v% BSA (66kDa) 1X PBS buffer solution, weigh 0.2g BSA powder and dissolve it in 40ml 1X PBS buffer solution, and stir at room temperature for 10min until it is evenly dissolved.

[0064] PEG (6kDa) / BSA was prepared at a solute mass ratio of 5:1, so 1 g of PEG powder was weighed and dissolved in 10 ml of 1XPBS buffer solution, and magnetic stirring was performed in a 50°C oil bath until the solution was uniformly dissolved.

[0065] Subsequently, the protein solution was mixed with the PEG reagent (50 ml in total) and incubated in a beaker at room temperature overnight using magnetic stirring.

[0066] The mixed solution was then poured into a centrifuge tube, which was frozen with liquid nitrogen, capped with aluminum foil and placed in a freeze dryer with a freezing parameter of -50°C / 3.0Pa for freeze drying overnight.

[0067] 2. Preparation of polylactic acid drug-loaded nanofibers using electrospinning technology

[0068] Weigh 0.521g of PEG-modified BSA freeze-dried powder and dissolve it in 20ml spinning solution. In this embodiment, the electrospinning medium in the spinning solution is polylactic acid (poly(lactic acid)(PLA)). The spinning solvent of the spinning solution is a mixed solution of dichloromethane and dimethylpropionamide in a volume ratio of 9:1. Weigh 1.186g of polylactic acid to prepare the spinning solution at a concentration of 8w / v%. Electrospinning process parameters: 25°C, 50%RH, positive pressure 15kV, negative pressure -1kV. Spinning distance ~15cm. Syringe specifications: 10ml. The spinning solution propulsion speed is 1.5ml / h. Collect on a release paper carrier using a roller shaft, roller speed: 1000rpm. Obtain BSA / polylactic acid nanofibers.

[0069] According to statistics, the diameter of the prepared BSA / polylactic acid nanofibers is 0.335±0.143μm.

[0070] 3. Chemical method + mechanical stirring method to shorten drug-loaded nanofibers

[0071] The BSA / PLA nanofibers were cut by aminolysis reaction combined with mechanical shearing to obtain short-cut BSA / PLA nanofibers.

[0072] Weigh 0.1688g of BSA / PLA nanofiber cloth and cut the nanofiber cloth into 2×2cm^2. Then, weigh an excess of 16g ​​of 1,6-hexanediamine and dissolve it in 144.25g of isopropanol. Add the BSA / PLA nanofiber cloth to the 1,6-hexanediamine isopropanol solution, heat it in an oil bath at 37°C, stir at 500rpm, and keep it warm for 3 hours.

[0073] The solution after the reaction was centrifuged at 10000 rpm for 10 min, and then washed with isopropanol three times. The short-cut BSA / polylactic acid nanofibers were then dispersed in 5 ml of tert-butyl alcohol, frozen in liquid nitrogen, and freeze-dried to obtain short-cut BSA / polylactic acid nanofibers.

[0074] The microstructure of chopped BSA / PLA nanofibers is shown in Figure 2. Figure 1 As shown, there are micropores on the surface of the nanofibers, and there are radial pores along the radial direction. The length of the short-cut nanofibers is 5.6±1.5 μm.

[0075] 4. Composite of chopped BSA / PLA nanofiber aerogel and porous bioactive ceramics

[0076] 0.0225 g of the short-cut BSA / polylactic acid nanofibers obtained in step 3 were weighed and dispersed in 2 ml of tert-butyl alcohol, and then two porous bioceramics β-TCP (diameter 6 mm, thickness 2 mm) were placed in the solution and subjected to vacuum revolution and rotation stirring treatment at a speed of 2000 rpm for 3 min and an air pressure of 0.5 Pa. Then the solution was taken out, frozen in liquid nitrogen, and freeze-dried for 24 hours.

[0077] Figure 2 The macroscopic photograph of the appearance of the composite of short-cut BSA / polylactic acid nanofiber aerogel and porous bioceramic β-TCP is shown. It can be seen that the porous bioceramic β-TCP still maintains a good round sheet shape, but the boundary regularity is poor. Figure 3 The SEM observation photograph of the porous bioceramic β-TCP cut from the central interface is shown, from which it can be seen that the short-cut BSA / polylactic acid nanofiber aerogel is filled in the internal pores of the porous bioceramic β-TCP, and some short-cut BSA / polylactic acid nanofibers are attached to the internal pore walls.

[0078] BSA protein release curve Figure 4 As shown in the curve. From the figure, it can be seen that the drug is rapidly released by 30% on the first day, and then released steadily.

[0079] Example 2

[0080] The method for preparing short-cut BSA / polylactic acid nanofibers is the same as that in Example 1.

[0081] The difference from Example 1 is that

[0082] However, in this embodiment, the method of compounding the short-cut BSA / polylactic acid nanofibers with the porous bioceramic β-TCP is different. Specifically, as follows:

[0083] Weigh 0.026g of short-cut drug-loaded polylactic acid nanofibers (i.e. short-cut BSA / polylactic acid nanofibers), disperse into 1w / w% sodium alginate solution, stir magnetically for 1h at a speed of ~800rpm, and perform vacuum stirring and degassing treatment (first at 200rpm for 30s, then at 1800rpm for 2min, with the vacuum degree maintained at 0.5Pa).

[0084] Then, two porous bioceramics β-TCP (with a diameter of 6 mm and a thickness of 2 mm) were added into the sodium alginate solution of short-cut drug-loaded polylactic acid nanofibers and degassed under vacuum stirring (2000 rpm, 5 min).

[0085] The porous bioceramic β-TCP was taken out and placed in a 2w / w% calcium chloride solution for 5 minutes to allow sodium ions and calcium ions to exchange and solidify to form a gel. After that, the porous bioceramic β-TCP was taken out and directly frozen for 10 minutes, and finally vacuum dried. The internal microstructure of the short-cut drug-loaded polymer nanofiber aerogel and the porous bioceramic β-TCP composite was obtained as shown in FIG. Figure 5 As shown in the figure, it can be seen that sporadic short-cut fibers are fixed by sodium alginate gel, and there are some short-cut nanofibers on the inner pore surface of the porous bioceramic β-TCP.

[0086] Example 3

[0087] The short-cut SDF-1α / polylactic acid nanofibers and porous bioceramic β-TCP are used as examples for explanation.

[0088] The specific method is as follows:

[0089] 1. Polyethylene glycol (PEG) solubilization modification of bovine serum albumin (BSA)

[0090] First, prepare 0.5w / v% BSA (66kDa) 1X PBS buffer solution, weigh 0.015g BSA powder and dissolve it in 3ml 1X PBS buffer solution, and stir at room temperature for 10-15min until it is evenly dissolved.

[0091] 1.0 mg / ml growth factor SDF-1α In this step, growth factor SDF-1α was added to BSA 1X PBS buffer solution at a loading amount of 123 μg.

[0092] PEG (6kDa) / BSA was prepared according to the mass ratio of the solute of 5:1, so 0.075g of PEG powder was weighed and dissolved in 0.75ml of 1X PBS buffer solution, and magnetic stirring was performed in a 50°C oil bath until the solution was uniform.

[0093] Subsequently, the protein solution was mixed with the PEG reagent (4.05 ml in total) and incubated in a beaker at room temperature using magnetic stirring for 24 h.

[0094] The mixed solution was then poured into a centrifuge tube, which was frozen with liquid nitrogen. Subsequently, the tube was sealed with aluminum foil and placed in a freeze dryer with a freezing parameter of -50°C / 3.0 Pa for freeze drying overnight.

[0095] 2. Preparation of polylactic acid drug-loaded nanofibers using electrospinning technology

[0096] The prepared SDF-1α / BSA freeze-dried powder was dissolved in 7.77 ml of spinning solution. The electrospinning medium was 0.6175 g of poly(lactic acid)(PLA). The spinning solvent was dichloromethane and dimethylpropionamide (volume ratio 9:1). The concentration of the spinning solution was 8 w / v%. Electrospinning process parameters: 27.2°C, 48-50% RH, positive pressure: 15 kV, negative pressure: -1 kV. Spinning distance ~17 cm. Syringe specification: 2.5 ml. Syringe push speed: 1-1.5 ml / h. The roller shaft was used to collect on an aluminum foil carrier, and the roller speed was 1000 rpm.

[0097] According to statistics, the diameter of the prepared SDF-1α / polylactic acid nanofibers is 0.602±0.202μm, and the microscopic morphology is as follows Figure 6 shown.

[0098] 3. Chemical method + mechanical stirring method to shorten drug-loaded nanofibers

[0099] The drug-loaded polylactic acid nanofibers were cut by aminolysis reaction combined with mechanical shearing to obtain short-cut drug-loaded polylactic acid nanofibers. Weigh the mass of SDF-1α / polylactic acid nanofiber cloth (about 0.10-0.15g) of A4 paper and cut it into 2x2 cm^2. Subsequently, weigh an excess of 16g ​​1,6-hexanediamine and dissolve it in 144.25g isopropanol. Add the rags to the 1,6-hexanediamine isopropanol solution, heat in an oil bath at 37°C, stir at 500rpm, and keep warm for 5-6 hours.

[0100] The solution after the reaction was centrifuged at 10000 rpm for 10 min, and then washed with isopropanol three times. Then, the short-cut SDF-1α / polylactic acid nanofibers were dispersed with 10 ml of tert-butyl alcohol, frozen in liquid nitrogen, and freeze-dried.

[0101] The length of short-cut drug-loaded polymer nanofibers is concentrated in the range of 10-20 μm.

[0102] 4. Composite of short-cut SDF-1α / polylactic acid nanofiber aerogel and porous bioactive ceramics

[0103] Weigh an appropriate amount of short-cut loaded SDF-1α / polylactic acid nanofibers and disperse them in 12 ml of tert-butyl alcohol at a concentration of 9.95 mg / ml. Then put 10 porous bioceramic β-TCP sheets (6 mm in diameter and 2 mm in thickness) into 1.5 ml of the solution and perform vacuum revolution and rotation stirring at a speed of 2000 rpm for 3 min and an air pressure of 0.5 Pa. Then take them out, freeze them in liquid nitrogen, and freeze-dry them for 24 hours.

[0104] At the same time, the same preparation process was used to prepare non-drug-loaded chopped polylactic acid nanofibers (i.e., polylactic acid nanofibers were directly prepared using the spinning solution without adding SDF-1α / BSA freeze-dried powder), and they were composited with porous bioceramic β-TCP (the composite method was the same as step 4 above) to evaluate the SDF-1α / polylactic acid chopped nanofiber aerogel and porous bioceramic β-TCP composite scaffold.

[0105] By constructing a rat cranial SDF-1α / polylactic acid short-cut nanofiber aerogel and porous bioceramic β-TCP composite scaffold bone defect model, Micro-CT detection and bone mass statistics were used to observe the effect of repairing bone defects, confirming that short-cut SDF-1α / polylactic acid nanofiber aerogel and porous bioceramic β-TCP composite scaffold has the best osteogenesis effect on repairing bone defects. Figure 7 shown.

[0106] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic, characterized in that: The following steps are involved: (1) performing polyethylene glycol solubilization modification on the protein drug to obtain a polyethylene glycol-modified protein drug lyophilized powder; (2) preparing a polymer electrospinning solution, adding a lyophilized powder of a protein drug modified with polyethylene glycol to the polymer electrospinning solution, and then performing electrospinning to obtain a drug-loaded polymer nanofiber membrane; (3) preparing the drug-loaded polymer nanofiber membrane into short-cut drug-loaded polymer nanofibers through chemical and mechanical shearing; (4) The short-cut drug-loaded polymer nanofibers are prepared into a dispersion, and the porous bioactive ceramic is immersed in the dispersion containing the short-cut drug-loaded polymer nanofibers. The short-cut drug-loaded polymer nanofibers and the porous bioactive ceramic are composited by vacuum stirring impregnation and freeze-drying to obtain a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic.

2. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (1), the protein drug is selected from a single protein or a combination of multiple proteins.

3. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (1), the method for obtaining a polyethylene glycol-modified protein drug lyophilized powder comprises the following steps: (1.1) preparing a buffer solution, dissolving the protein drug in the buffer solution, and adding the growth factor to the buffer solution to obtain a protein solution; (1.2) dissolving polyethylene glycol in a buffer solution and stirring until the solution is uniformly dissolved to obtain a polyethylene glycol solution; (1.3) The protein solution and the polyethylene glycol solution are mixed and stirred, and then frozen to obtain a polyethylene glycol-modified protein drug freeze-dried powder.

4. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 3, characterized in that: In step (1.1), in the protein solution, the concentration of the protein drug is 1-10 mg / ml, and the concentration of the growth factor is 0.5-1 mg / ml; In step (1.2), a polyethylene glycol solution is prepared according to a weight ratio of polyethylene glycol to protein drug of 2-10:1; In step (1.3), the freezing conditions are: -40 to -60°C, and freeze-drying for 6 to 12 hours.

5. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (2), the electrospinning medium in the polymer electrospinning solution is a medical polymer material selected from one or a combination of polylactic acid, polycaprolactone, polylactic acid-glycolic acid copolymer or polycarboxylic acid; In step (2), the spinning solvent in the polymer electrospinning solution is a mixed solution of dichloromethane and dimethylpropionamide; In step (2), the concentration of the electrospinning medium in the polymer electrospinning solution is 5-15 w / v%.

6. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (2), after the polyethylene glycol-modified protein drug freeze-dried powder is added to the polymer electrospinning solution, the concentration of the polyethylene glycol-modified protein drug freeze-dried powder is 10-50 mg / ml; In step (2), the conditions for electrospinning are: 20-28°C, 50-60% RH, positive pressure: 15-17 kV, negative pressure: -1--4 kV, spinning distance 13-19 cm, collected on release paper or aluminum foil carrier using a roller shaft, roller speed: 200-1000 rpm.

7. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (3), the method for shearing the drug-loaded polymer nanofiber membrane into short-cut drug-loaded polymer nanofibers is: The drug-loaded polymer nanofiber membrane is cut into block-shaped drug-loaded polymer nanofiber blocks. Subsequently, an excess of 1,6-hexanediamine is weighed and dissolved in isopropanol. The drug-loaded polymer nanofiber blocks are added to the 1,6-hexanediamine isopropanol solution, heated to 35-40°C, stirred at 500-800rpm, and kept warm for 3-5 hours to obtain short-cut drug-loaded polymer nanofibers with a length in the range of 2-20μm. The solution is then centrifuged and washed at least 3 times with anhydrous ethanol or isopropanol. Subsequently, the short-cut drug-loaded nanofibers are dispersed with tert-butyl alcohol, frozen with liquid nitrogen, and freeze-dried to obtain short-cut drug-loaded polymer nanofibers.

8. The method for preparing a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic according to claim 1, characterized in that: In step (4), the short-cut drug-loaded polymer nanofibers are dispersed in tert-butyl alcohol to prepare a dispersion, and the porous bioactive ceramic is immersed in the dispersion containing the short-cut drug-loaded polymer nanofibers, and a vacuum revolution and rotation stirring treatment is performed to achieve the composite of the short-cut drug-loaded polymer nanofibers and the porous bioactive ceramic, and then the porous bioactive ceramic is taken out and immediately subjected to liquid nitrogen freezing and drying to obtain a composite scaffold of short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic; The concentration of short-cut drug-loaded polymer nanofibers in the dispersion is 5-50 mg / ml; The ratio of the apparent volume of the porous bioactive ceramic to the volume of the dispersion liquid is 5%-50%.

9. A short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold, characterized in that: The method according to any one of claims 1 to 8 is used to prepare the present invention.

10. Use of the short-cut drug-loaded polymer nanofiber aerogel and porous bioactive ceramic composite scaffold as claimed in claim 9 as a bone repair material.